News: Somaxon Pharmaceuticals, Inc. (SOMX.O)

SOMX.O on Consolidated Issue listed on NASDAQ Capital Market

1.15USD
3:08pm EST
Price Change (% chg)

$0.03 (+2.68%)
Prev Close
$1.12
Open
$1.13
Day's High
$1.19
Day's Low
$1.13
Volume
1,470,966
Avg. Vol
7,623,835
52-wk High
$4.80
52-wk Low
$0.17

view news for:
Select another date:

Mon, Dec 7 2009

UPDATE 2-FDA denies approval for Somaxon insomnia drug again

* Shares fall as much 68 pct (Adds company comment, updates share movement)

Continue Reading

Somaxon drops after complete response letter

NEW YORK (Reuters) - Somaxon Pharmaceuticals Inc shares plunged 71.7 percent to $1 in premarket trade on Monday after the company said it had received a complete response letter from the U.S. Food and Drug Administration stating that Somaxon's Silenor new drug application did not meet the approval standard for efficacy.

UPDATE 1-Somaxon: FDA denies approval for insomnia drug

* FDA denies approval for insomnia drug in present form

UPDATE 1-FDA extends Somaxon's insomnia drug review by 3 months

Nov 24 (Reuters) - Specialty pharmaceutical company Somaxon Pharmaceuticals Inc said U.S. health regulators extended the review of its experimental insomnia treatment by up to three months.

US-RESEARCH/ (NON-S&P500)

Moneygram KeyBanc Upgrades to hold from underweight International --------------------------------------------------------------- ------------ Pacer International Baird Raises price target to $18 from $16; keeps neutral rating --------------------------------------------------------------- ------------ PNM Resources Citigroup Cuts to hold from buy --------------------

Somaxon Pharma CEO resigns, interim head named

Dec 6 (Reuters) - Somaxon Pharmaceuticals Inc said Kenneth Cohen resigned as chief executive officer and president of the company, effective Dec. 31, and named David Hale interim CEO, effective Jan. 1, 2008.

US RESEARCH NEWS-Goldman raises Vertex Pharmaceuticals to buy

Following are the research actions reported by Reuters on Thursday as of 0713 ET --------------------------------------------------------------- ------------ STOCK RESEARCH BY ACTION Vertex Pharmaceuticals Goldman Sachs Raises to buy from neutral --------------------------------------------------------------- ------------ Ctrip.com Bear Stearns Starts with outperform rating; price

Somaxon Pharmaceuticals Q3 results

SOMAXON PHARMACEUTICALS INC : * Third quarter earnings per share loss $0.31 * Reuters Estimates third quarter earnings per share view $-0.39

FACTBOX: NASDAQ NeuroInsights Neurotech Index

The following are the companies included in the Nasdaq NeuroInsights Neurotech Index, (NASDAQ:NERV) (NASDAQ:NRVX) which will be launched on September 25

TABLE-Somaxon Q2 loss narrows

SOMAXON PHARMACEUTICALS INC. (In $) Latest Yr-ago qtr Loss/shr (diluted) 0.33 0.82 Net loss^ (million) 6.0 14.7 ^Applicable to common stockholders Reuters Estimates: Loss/shr $0.42. (Reporting by Dilipp S. Nag in Bangalore)

Select another date:

Market Views

» More SOMX.O Market Views

Press Releases

view news for: